Inpatient DVT Management: Anticoagulation Strategy
For inpatient management of acute DVT, initiate anticoagulation with low-molecular-weight heparin (LMWH) or fondaparinux as first-line therapy over unfractionated heparin (UFH), unless specific contraindications exist. 1
Initial Anticoagulation Choice
The most recent CHEST guidelines (2024) provide clear hierarchy for initial anticoagulation 1:
- LMWH or fondaparinux are preferred over IV UFH (weak recommendation, low-certainty evidence for LMWH; weak recommendation, low-certainty evidence for fondaparinux)
- LMWH is preferred over subcutaneous UFH (weak recommendation, moderate-certainty evidence)
LMWH Dosing Regimens
Standard FDA-approved dosing 2:
- Enoxaparin: 1 mg/kg subcutaneously twice daily OR 1.5 mg/kg once daily
- Dalteparin: 200 IU/kg subcutaneously once daily
Once-daily dosing is preferred over twice-daily when using the full anticoagulant dose 2. For once-daily enoxaparin, use 1.5 mg/kg (not the 1 mg/kg twice-daily dose reduced to once daily).
When to Use UFH Instead
Reserve UFH for specific situations 2, 3:
- Severe renal insufficiency (creatinine clearance <30 mL/min) - LMWH accumulation risk
- High bleeding risk requiring rapid reversibility
- Hemodynamic instability
- Morbid obesity where weight-based LMWH dosing is uncertain
UFH dosing: 80 units/kg IV bolus, then 18 units/kg/hour continuous infusion 3. Target aPTT ratio 1.5-2.5 (corresponding to anti-Factor Xa level 0.3-0.7 IU/mL) 2.
Transition to Oral Anticoagulation
Direct Oral Anticoagulants (DOACs) - Preferred
The 2024 CHEST guidelines strongly recommend DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) over warfarin for treatment-phase anticoagulation (strong recommendation, moderate-certainty evidence) 1, 4.
Key advantage: Rivaroxaban and apixaban can be started immediately without requiring parenteral overlap, simplifying inpatient management 2:
- Rivaroxaban: 15 mg twice daily for 21 days, then 20 mg once daily
- Apixaban: Can be started directly (specific dosing per manufacturer)
For edoxaban or dabigatran: Requires at least 5 days of parenteral anticoagulation first 1.
Warfarin - Alternative Option
If warfarin is chosen 1:
- Start warfarin on day 1 (same day as parenteral anticoagulation)
- Continue parenteral anticoagulation minimum 5 days AND until INR ≥2.0 for at least 24 hours
- Target INR 2.0-3.0 (target 2.5)
- Initial warfarin dose typically 5 mg daily, adjusted based on patient factors 2
Treatment Duration
Minimum 3 months of anticoagulation for all acute VTE without contraindication (strong recommendation, moderate-certainty evidence) 1.
Duration Algorithm:
DVT provoked by major transient risk factor (e.g., recent surgery): Stop at 3 months (strong recommendation) 1
Unprovoked DVT or persistent risk factors: Extended anticoagulation beyond 3 months with periodic reassessment (strong recommendation) 1, 4
Cancer-associated thrombosis: Extended anticoagulation (no scheduled stop date) - prefer oral Xa inhibitors (apixaban, edoxaban, rivaroxaban) over LMWH (strong recommendation) 5, 1, 4
Inpatient vs Outpatient Management
For uncomplicated DVT with adequate home circumstances, recommend home treatment over hospitalization (strong recommendation, moderate-certainty evidence) 1, 6.
Criteria requiring hospitalization:
- Hemodynamic instability
- High bleeding risk
- Severe symptoms requiring IV analgesia
- Inadequate home support
- Inability to afford medications
- Concomitant conditions requiring admission
- Suspected PE with intermediate-high or high risk 6
Critical Monitoring
Heparin-Induced Thrombocytopenia (HIT)
Monitor platelet counts every 2-3 days from day 4 to day 14 in patients receiving UFH with HIT risk ≥1% 2. HIT risk with UFH may reach 5%, particularly post-orthopedic surgery. LMWH has lower HIT risk but cross-reactivity exists.
Renal Function
LMWH is contraindicated if creatinine clearance <30 mL/min 2. Use UFH or adjust to clinical situation.
Common Pitfalls
Using prophylactic LMWH doses for treatment - ensure full therapeutic dosing (enoxaparin 1 mg/kg twice daily or 1.5 mg/kg once daily, NOT prophylactic 40 mg daily)
Stopping parenteral anticoagulation too early with warfarin - must continue minimum 5 days AND until INR therapeutic ≥24 hours
Not considering DOACs first-line - 2024 guidelines strongly favor DOACs over warfarin for most patients
Forgetting renal dosing adjustments - DOACs and LMWH both require renal function assessment
Inadequate overlap period - premature discontinuation of parenteral therapy increases thrombotic risk